Panacea Biotec has received a Letter of Award from UNICEF for supply of 115 million doses of its bivalent oral polio vaccine (bOPV) worth ~US$ 14.95 million (~Rs.127 crore) in CY2025.Powered by Capital Market - Live News

Net profit of Panacea Biotec reported to Rs 4.71 crore in the quarter ended September 2024 as against net loss of Rs 8.29 crore during the previous quarter ended September 2023. Sales rose 3.03% to Rs 147.35 crore in the quarter ended September 2024 as against Rs 143.02 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales147.35143.02 3 OPM %4.75-2.49 - PBDT10.67-1.24 LP PBT1.99-10.55 LP NP4.71-8.29 LP Powered by Capital Market - Live News

Panacea Biotec will hold a meeting of the Board of Directors of the Company on 13 November 2024Powered by Capital Market - Live News

Panacea Biotec announced that the Annual General Meeting (AGM) of the company will be held on 27 September 2024.Powered by Capital Market - Live News

Net loss of Panacea Biotec reported to Rs 15.88 crore in the quarter ended June 2024 as against net profit of Rs 10.98 crore during the previous quarter ended June 2023. Sales declined 10.43% to Rs 115.72 crore in the quarter ended June 2024 as against Rs 129.19 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales115.72129.19 -10 OPM %-12.09-7.98 - PBDT-11.06-5.23 -111 PBT-19.79-14.71 -35 NP-15.8810.98 PL Powered by Capital Market - Live News